These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 24697653)
1. IL-6 in diabetes and cardiovascular complications. Qu D; Liu J; Lau CW; Huang Y Br J Pharmacol; 2014 Aug; 171(15):3595-603. PubMed ID: 24697653 [TBL] [Abstract][Full Text] [Related]
2. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling. Reeh H; Rudolph N; Billing U; Christen H; Streif S; Bullinger E; Schliemann-Bullinger M; Findeisen R; Schaper F; Huber HJ; Dittrich A Cell Commun Signal; 2019 May; 17(1):46. PubMed ID: 31101051 [TBL] [Abstract][Full Text] [Related]
3. IL-6 signalling pathways and the development of type 2 diabetes. Akbari M; Hassan-Zadeh V Inflammopharmacology; 2018 Jun; 26(3):685-698. PubMed ID: 29508109 [TBL] [Abstract][Full Text] [Related]
5. Versatile functions for IL-6 in metabolism and cancer. Mauer J; Denson JL; Brüning JC Trends Immunol; 2015 Feb; 36(2):92-101. PubMed ID: 25616716 [TBL] [Abstract][Full Text] [Related]
6. Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. Xu E; Pereira MMA; Karakasilioti I; Theurich S; Al-Maarri M; Rappl G; Waisman A; Wunderlich FT; Brüning JC Nat Commun; 2017 May; 8():14803. PubMed ID: 28466852 [TBL] [Abstract][Full Text] [Related]
7. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure. Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473 [TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Rani V; Deep G; Singh RK; Palle K; Yadav UC Life Sci; 2016 Mar; 148():183-93. PubMed ID: 26851532 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Owczarczyk-Saczonek A; Placek W Int J Dermatol; 2017 Mar; 56(3):260-268. PubMed ID: 27696392 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-6: A Masterplayer in the Cytokine Network. Uciechowski P; Dempke WCM Oncology; 2020; 98(3):131-137. PubMed ID: 31958792 [TBL] [Abstract][Full Text] [Related]
11. Scaffold Proteins: From Coordinating Signaling Pathways to Metabolic Regulation. Mugabo Y; Lim GE Endocrinology; 2018 Nov; 159(11):3615-3630. PubMed ID: 30204866 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 "Trans-Signaling" and Ischemic Vascular Disease: The Important Role of Soluble gp130. Morieri ML; Passaro A; Zuliani G Mediators Inflamm; 2017; 2017():1396398. PubMed ID: 28250574 [TBL] [Abstract][Full Text] [Related]
13. The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. Herder C; Dalmas E; Böni-Schnetzler M; Donath MY Trends Endocrinol Metab; 2015 Oct; 26(10):551-563. PubMed ID: 26412156 [TBL] [Abstract][Full Text] [Related]
14. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Heinrich PC; Behrmann I; Haan S; Hermanns HM; Müller-Newen G; Schaper F Biochem J; 2003 Aug; 374(Pt 1):1-20. PubMed ID: 12773095 [TBL] [Abstract][Full Text] [Related]
15. Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukin-8 (CXCL8), Myeloid-Related Protein 8/Myeloid-Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease. Kienhorst LB; van Lochem E; Kievit W; Dalbeth N; Merriman ME; Phipps-Green A; Loof A; van Heerde W; Vermeulen S; Stamp LK; van Koolwijk E; de Graaf J; Holzinger D; Roth J; Janssens HJ; Merriman TR; Broen JC; Janssen M; Radstake TR Arthritis Rheumatol; 2015 Dec; 67(12):3303-13. PubMed ID: 26248007 [TBL] [Abstract][Full Text] [Related]
16. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Jones SA; Jenkins BJ Nat Rev Immunol; 2018 Dec; 18(12):773-789. PubMed ID: 30254251 [TBL] [Abstract][Full Text] [Related]
17. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Garbers C; Aparicio-Siegmund S; Rose-John S Curr Opin Immunol; 2015 Jun; 34():75-82. PubMed ID: 25749511 [TBL] [Abstract][Full Text] [Related]
18. Role of Caveolin-1 in Diabetes and Its Complications. Haddad D; Al Madhoun A; Nizam R; Al-Mulla F Oxid Med Cell Longev; 2020; 2020():9761539. PubMed ID: 32082483 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases. Chen WY; Tsai TH; Yang JL; Li LC Cell Physiol Biochem; 2018; 49(1):349-358. PubMed ID: 30138941 [TBL] [Abstract][Full Text] [Related]
20. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Kreiner FF; Kraaijenhof JM; von Herrath M; Hovingh GKK; von Scholten BJ Expert Rev Clin Immunol; 2022 Apr; 18(4):377-389. PubMed ID: 35212585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]